HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Rhea-AI Summary
HCW Biologics (NASDAQ: HCWB) adjourned its Special Meeting of Stockholders held April 27, 2026, for lack of a quorum; no business was conducted and proposals will be moved to the Annual Meeting on June 15, 2026 at 10:00 a.m. ET.
The company continues to solicit votes on two proposals tied to warrants issued to Armistice Capital Master Fund Ltd., following a $17.4 million investment. The warrants would permit purchase of up to 5,497,702 shares at an exercise price of $0.6055. The company must seek shareholder approval every 60 days and will incur ongoing costs until approval is obtained.
Positive
- Armistice provided $17.4 million in financing
- Warrants grant potential equity funding via $0.6055 exercise price
- Company consolidated votes to Annual Meeting on June 15, 2026
Negative
- Potential dilution: warrants to buy 5,497,702 shares
- Company must seek approval every 60 days until obtained
- Ongoing costs from repeated shareholder solicitations
News Market Reaction – HCWB
In the May 1 session, HCWB declined 4.07%, reflecting a moderate negative market reaction. Argus tracked a peak move of +31.3% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Preclinical data update | Positive | +16.9% | HCW11-018b T-cell engager data showing tumor shrinkage and metastasis prevention. |
| Mar 31 | Earnings and outlook | Negative | -16.7% | 2025 results with minimal revenue, losses, going-concern doubt and Nasdaq bid-price issues. |
| Mar 17 | Licensing transaction | Positive | -6.3% | $7.0M upfront package from Trimmune for HCW11-006 license and future milestones. |
| Mar 16 | Research publication | Positive | +60.9% | Science Advances paper showing HCW9206-generated CAR-T cells with improved persistence and activity. |
| Mar 02 | Listing compliance | Positive | +1.7% | Nasdaq panel confirmed regained compliance with continued listing rules on Feb 26, 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has mostly seen price moves aligned with the apparent news tone, with one notable divergence on a positive licensing deal.
Over the past two months, HCWB has reported several clinically focused and financing-related milestones. Positive preclinical data for HCW11‑018b on Apr 27, 2026 and a Science Advances publication for HCW9206 on Mar 16, 2026 both saw strong gains. In contrast, the Mar 31, 2026 earnings and going‑concern disclosure coincided with a sharp decline. A $7.0M HCW11‑006 license on Mar 17, 2026 led to a negative reaction, diverging from its constructive tone. Today’s adjourned meeting and Armistice warrant proposals fit into this ongoing capital-structure and funding narrative.
Key Terms
warrants financial
quorum regulatory
proxy statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation today announced that the Company’s Special Meeting of Stockholders, held on April 27, 2026, at 10:00 a.m. Eastern Time (“Special Meeting”) was adjourned, without any business being conducted, due to lack of the required quorum and the matters were adjourned to the Annual Meeting of Stockholders.
The proposals presented to stockholders for their consideration at the Special Meeting will be included in the proposals presented to stockholders for their consideration for the Company’s Annual Meeting of Stockholders (“Annual Meeting”). The Annual Meeting is scheduled to take place virtually on June 15, 2026 at 10:00 a.m. Eastern Time.
During the adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals set forth in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on April 28, 2026.
The Company encourages all stockholders of record as of the record date of April 22, 2026 to vote in favor of these two proposals related warrants issued to Armistice Capital Master Fund Ltd. (“Armistice”). Armistice has invested
About HCW Biologics:
HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the actual success and potency of the Company’s immunotherapeutic treatments to disrupt the link between chronic inflammation and diseases; and the ability of the Company to reach quorum at the Annual Stockholder Meeting. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 31, 2026 and in other filings filed from time to time with the SEC.
Company Contact:
Rebecca Byam
Chief Financial Officer
rebeccabyam@hcwbiologics.com
